Nathan J. Dowden, Chief Operating Officer at Entrada Therapeutics, Inc. (TRDA), sold 100 shares at $15.01 ($2K) on 2022-09-15, disclosed to the SEC on 2022-09-19.
Scheduled sale ($2k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TRDA | SELL | 2024-09-30 | $14K | — | Filing → |
| TRDA | SELL | 2024-09-10 | $35K | — | Filing → |
| TRDA | SELL | 2024-08-20 | $873K | — | Filing → |